Hyderabad, Telangana, India, July 2026 – Dr. Reddy’s Laboratories has elevated Rahul Shroti to the role of Country Head – Emerging Markets (Sri Lanka, Maldives, Mauritius) while continuing to lead Business Development and Portfolio initiatives for the ISC region.
The appointment reflects the company’s confidence in Rahul’s ability to drive growth across strategically important emerging markets and further strengthen Dr. Reddy’s presence in South Asia and the Indian Subcontinent region. In his expanded leadership role, Rahul will be responsible for business growth, market expansion, portfolio strategy, partner management, commercial execution, and overall P&L performance across Sri Lanka, Maldives, and Mauritius.
Rahul has been associated with Dr. Reddy’s Laboratories for more than seven years and has played an instrumental role in expanding the company’s footprint across emerging markets. Over this period, he has successfully led business development initiatives, alliance management programs, portfolio expansion strategies, and commercial operations across multiple international markets.
Prior to his latest elevation, Rahul served as Country Lead – Emerging Markets and Lead – Business Development & Portfolio for the ISC region. In these roles, he was responsible for market strategy, sales growth, new product launches, portfolio building, regulatory coordination, alliance management, and identifying new business opportunities across emerging markets.
Earlier, as Manager – Business Development & Alliance Management for Emerging Markets, he led strategic partnerships, licensing transactions, distribution agreements, portfolio expansion initiatives, and commercialization programs. He worked closely with cross-functional teams spanning regulatory affairs, supply chain, finance, legal, medical affairs, and commercial operations to drive successful market execution and partner performance.
Before joining Dr. Reddy’s Laboratories in 2019, Rahul spent over five years with Torrent Pharmaceuticals, where he held leadership roles in Portfolio and Project Management. During his tenure, he managed product identification, portfolio planning, project execution, regulatory coordination, commercialization strategies, and business evaluation activities for global pharmaceutical markets.
His earlier experience includes assignments with AIOCD Awacs, IJCP Group, and Siemens Healthcare, where he gained exposure to pharmaceutical marketing, business development, healthcare market analysis, project management, and commercial strategy.
Throughout his career, Rahul has developed deep expertise across international business, emerging markets strategy, portfolio management, alliance management, business development, commercial operations, licensing, partner management, product launches, and P&L leadership. His ability to identify growth opportunities, build strategic partnerships, and execute market expansion strategies has contributed significantly to business growth across multiple geographies.
Rahul’s elevation comes at a time when emerging pharmaceutical markets continue to offer significant opportunities for growth, driven by increasing healthcare access, expanding patient populations, and rising demand for affordable medicines. His experience in navigating complex international markets and building sustainable business partnerships positions him well to lead Dr. Reddy’s next phase of growth across Sri Lanka, Maldives, and Mauritius.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company is driven by its purpose of “Good Health Can’t Wait” and is committed to providing access to affordable and innovative medicines worldwide.
The company offers a broad portfolio of products and services including APIs, generics, branded generics, biosimilars, and over-the-counter products. Dr. Reddy’s operates across major global markets including the United States, India, Russia & CIS, China, Brazil, and Europe, while continuing to invest in innovation, sustainability, digital healthcare, and access to medicines.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
